In tumor therapy, SIRT4 overexpression was found to inhibit glutamine metabolism and also inhibit the proliferation of rectal cancer cells by synergizing with glucose inhibitors; SIRT4 inhibits the invasion and migration ability of prostate cancer cells by inhibiting glutamine metabolism; besides SIRT4's ability to synergize with glutamine metabolism for tumor treatment, SIRT4 can also synergize with antitumor drugs. This evidence concerns the gene SIRT4 and prostate carcinoma.